Look back at pharma news in the week to April 23, 2021
By Barbara Obstoj-Cardwell. Editor
Notable news last week included Australia’s Kazia Therapeutics entering a licensing deal with Germany’s Evotec for worldwide rights to cancer candidate EVT801. French vaccine specialist Valneva has started Phase III evaluation of its COVID-19 candidate VLA200 in the UK. US biotech bluebird bio gave an update on its genetic disease portfolio last Tuesday and said it was withdrawing its beta thalassemia drug Zynteglo from the German market due to failed price negotiations. GlaxoSmithKline was granted US Food and Drug Administration approval for its checkpoint blocker Jemperli. Also, on Friday the FDA lifted its pause on the use of Johnson & Johnson’s COVID-19 Vaccine Janssen.
Kazia Therapeutics: New asset to target tumor lymphangiogenesis
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze